Home > Healthcare > Medical Devices > Diagnostic Devices > Breast Cancer Liquid Biopsy Market

Breast Cancer Liquid Biopsy Market Size

Report ID: GMI12188
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Breast Cancer Liquid Biopsy Market Size

The global breast cancer liquid biopsy market size was valued at USD 305.9 million in 2023 and is estimated to grow at a CAGR of 22.6% from 2024 to 2032. The market has experienced substantial growth driven by the rising incidence of breast cancer and advancements in cancer diagnostic technologies. Innovations such as liquid biopsy and next-generation sequencing (NGS) have gained popularity due to their high accuracy and minimally invasive characteristics.

To get key market trends

Download Free Sample

These advancements are revolutionizing cancer diagnostics by providing precise methods for cancer detection and monitoring. For instance, in 2019, the National Cancer Institute (NCI) reported that liquid biopsies could identify genetic mutations in over 70% of advanced cancer cases, enhancing early detection, supporting personalized treatment strategies, and improving patient outcomes. Thus, the increasing advantages and reliability of non-invasive techniques further bolster market demand.

Breast Cancer Liquid Biopsy Market Report Attributes
Report Attribute	Details
Base Year:	2023
Breast Cancer Liquid Biopsy Market Size in 2023:	USD 305.9 Million
Forecast Period:	2024 - 2032
Forecast Period 2024 - 2032 CAGR:	22.6%
2032 Value Projection:	USD 1.9 Billion
Historical Data for:	2021 - 2023
No. of Pages:	145
Tables, Charts & Figures:	116
Segments covered:	Biomarker, Products & Services, Sample Type, End Use, and Region
Growth Drivers:	Rising prevalence of breast cancer Technological advancements in liquid biopsy technique Rising awareness for early diagnosis and treatment Expansion of research and development
Pitfalls & Challenges:	High cost of biopsy devices Stringent regulatory requirements

Learn more about the key segments shaping this market

Download Free Sample

Furthermore, the growing awareness of inherited oncology conditions and genetic testing is fuelling demand for these technologies. This focus on early detection and personalized treatment leads to better patient outcomes, emphasizing targeted cancer therapies that leverage insights from advanced cancer biopsy techniques for diagnosis.

Breast cancer liquid biopsy is a non-invasive diagnostic technique that analyzes cancer biomarkers in blood samples to detect and monitor breast cancer. This method focuses on circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), providing insights into tumor characteristics, treatment response, and disease progression. Comparatively, liquid biopsies are easier to perform and can be repeated over time, enabling real-time monitoring of the disease compared to traditional biopsy techniques.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global breast cancer liquid biopsy industry was valued at USD 305.9 million in 2023 and is estimated to grow at a 22.6% CAGR from 2024 to 2032, driven by the rising incidence of breast cancer and advancements in diagnostic technologies.

The cfDNA segment dominated the global market and is anticipated to grow at a 22.5% CAGR over the forecast period due to its non-invasive nature and ability to provide real-time insights into tumor dynamics.

U.S. breast cancer liquid biopsy industry accounted for USD 133.3 million in 2023 and is anticipated to grow significantly during the forecast period, supported by advanced healthcare infrastructure and substantial R&D investments.

Key players in the industry include Datar Cancer Genetics, Epic Sciences, F. Hoffmann-La Roche, Genes2me, Illumina, Menarini Silicon Biosystems, Myriad Genetics, OncoDNA, and QIAGEN.